ABUS vs TFC · P/E 5.4, rev $6.2M vs rev $24.54B
Arbutus Biopharma Corp (ABUS) versus TFC (TFC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
TFC (TFC) common stock.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported TFC revenue for 2025-12-31 was $24.54B. Net income was $5.31B. Revenue was down 2.1% from 2024-12-31 to 2025-12-31. TFC currently screens at market cap $0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. TFC currently screens at market cap $0.
Not investment advice. Open the ABUS and TFC stock pages for the full models.
Not investment advice.